RICHTER SYNDROME
Clinical trials for RICHTER SYNDROME explained in plain language.
Never miss a new study
Get alerted when new RICHTER SYNDROME trials appear
Sign up with your email to follow new studies for RICHTER SYNDROME, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental cocktail targets aggressive lymphoma in early trial
Disease control OngoingThis early-phase trial is testing a combination of the immunotherapy drug atezolizumab, two chemotherapy drugs (gemcitabine and oxaliplatin), and the targeted antibody rituximab in 24 patients with transformed diffuse large B-cell lymphoma that has come back or stopped responding…
Matched conditions: RICHTER SYNDROME
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Triple therapy takes on aggressive blood cancer
Disease control OngoingThis phase 2 trial is testing whether adding a personalized cell therapy (liso-cel) to two existing drugs (nivolumab and ibrutinib) can help people with Richter's transformation, a rare and aggressive blood cancer. The study plans to enroll 9 participants and will measure how man…
Matched conditions: RICHTER SYNDROME
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New drug combo targets Hard-to-Treat blood cancers
Disease control OngoingThis early-phase study tests a new two-drug combination (pevonedistat and ibrutinib) in adults with chronic lymphocytic leukemia or non-Hodgkin lymphoma that has returned or no longer responds to standard therapy. The main goal is to find the safest dose and understand side effec…
Matched conditions: RICHTER SYNDROME
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
New drug duo shows promise for Tough-to-Treat blood cancers
Disease control OngoingThis study tests a combination of two drugs, duvelisib and venetoclax, in 55 people with relapsed or refractory chronic lymphocytic leukemia (CLL) or Richter's syndrome. Duvelisib blocks a protein that helps cancer cells survive, while venetoclax targets another survival protein.…
Matched conditions: RICHTER SYNDROME
Phase: PHASE1, PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New Three-Drug cocktail aims to tackle tough lymphomas
Disease control OngoingThis study tests a new combination of three drugs—ALX148, lenalidomide, and rituximab—in people with B-cell non-Hodgkin lymphoma that has come back or not responded to treatment. The goal is to find the best dose and see how well the combo works at shrinking or eliminating tumors…
Matched conditions: RICHTER SYNDROME
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Triple-Drug attack aims to wipe out Hard-to-Treat leukemia
Disease control OngoingThis phase 2 trial tests a combination of three drugs—atezolizumab, obinutuzumab, and venetoclax—in 50 adults with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma, or Richter syndrome that has returned or not responded to prior treatment. The goal is to see if the …
Matched conditions: RICHTER SYNDROME
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
New drug cocktail shows promise for Tough-to-Treat lymphomas
Disease control OngoingThis early-phase trial tests a combination of two drugs—copanlisib and nivolumab—in people with Richter's transformation or certain non-Hodgkin lymphomas that have become aggressive. The study aims to find the best dose and check for side effects. A total of 27 participants will …
Matched conditions: RICHTER SYNDROME
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Scientists dive deep into Epcoritamab's effects on Hard-to-Treat blood cancers
Knowledge-focused OngoingThis study looks at blood, lymph node, and bone marrow samples from 5 people with chronic lymphocytic leukemia or Richter syndrome who are receiving the drug epcoritamab. Researchers want to understand how the drug changes immune cells and tumor cells over time. The goal is to le…
Matched conditions: RICHTER SYNDROME
Phase: PHASE1 • Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:06 UTC